A. Carrasco-Yalan

Advances in the therapy of chronic idiopathic myelofibrosis.

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2006, The oncologist.

Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation

E. Shpall, U. Popat, M. Qazilbash, 2007, Leukemia.

The CD271 expression could be alone for establisher phenotypic marker in Bone Marrow derived mesenchymal stem cells.

A. Carrasco-Yalan, K. Gazarian, O. Gonzalez-Ramella, 2011, Folia histochemica et cytobiologica.

Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.

U. Popat, M. Qazilbash, D. Couriel, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease.

S. Giralt, G. Ruiz-Argüelles, D. Gómez-Almaguer, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The CD 271 expression could be alone for establisher phenotypic marker in Bone Marrow derived mesenchymal stem cells

A. Carrasco-Yalan, K. Gazarian, O. Gonzalez-Ramella, 2011 .

Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.

A. Alousi, R. Champlin, M. de Lima, 2007, Blood.

Distribution and Pathology Characteristics of Non Hodgkin Lymphoma in Peru: A Study of 1014 Cases Using WHO Classification of Lymphoid Neoplasm.

A. Carrasco-Yalan, B. Beltrán, P. Quiñones, 2007 .